NCT00015990View on ClinicalTrials.gov

Thalidomide in Treating Patients With Myelodysplastic Syndrome

PHASE2CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

April 30, 2001

Primary Completion Date

February 28, 2007

Conditions
Chronic Myelomonocytic Leukemiade Novo Myelodysplastic SyndromesPreviously Treated Myelodysplastic SyndromesRefractory AnemiaRefractory Anemia With Excess BlastsRefractory Anemia With Excess Blasts in TransformationRefractory Anemia With Ringed SideroblastsSecondary Myelodysplastic Syndromes
Interventions
DRUG

thalidomide

Given orally

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

55905

North Central Cancer Treatment Group, Rochester

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00015990 - Thalidomide in Treating Patients With Myelodysplastic Syndrome | Biotech Hunter | Biotech Hunter